Scancell Takeover Rumours (SCLP)

JakNife, Why would they convert now? I don't follow your logic. Redmile already hold 28.9% of Scancell and will not want to trigger a mandatory takeover so why convert when they already hold just under 270m shares which they could sell if they want to take some profit - nearly 100m of those were bought at 5.5p. So why would they convert and risk triggering a mandatory offer, but more importantly damage sentiment and adversely impact the value of what is by far the greater portion of their investment in SCLP ie. their existing holding? By the way as part of the agreement to extend the redemption date the terms of the 13p CLNs were changed so they can now be converted at any time upon Redmile's request.

Yup - and the other point that is really obvious to me - there is little value in being overexposed - always keep some money aside ready to pounce if the news is fantastic. The market won't be close enough to move immediately. A takeover would negate that but for me that's highly unlikely yet.

Marcus Re The potential for even Moditope alone in multi-billions so for me it is a case of sit back and wait for a huge takeover. Yep a few I know are doing exactly that with expectations as early as H2 2025. Some know more than others so views vary of course.

Well the thing that got me hooked a few years back was the 5 year Scib data. I have tried to educate myself by listening to every word Lindy and Cliff Holloway presented over the years. Amazingly for a Bio, everything appears to be working! Immunobody, Moditope, Glymabs and Avidimab. The potential for even Moditope alone is multi-billions so for me it is a case of sit back and wait for a huge takeover. I`ll not get too concerned about spikes and troughs. In a perfect world I would love an all share or part cash offer for CGT reasons. I would not even mind owning Roche,Eli Lilly, Merck or BMS stock ! ;-)

Yes Bermuda. The results of Modi-1 with IPI/Nivo in H1 2025 will be key. If they are very good then I think Scancell becomes a takeover target possibly sooner rather than later.

It will be interesting to see what happens. I still think the whole Immunobody platform could be licensed or a full takeover. iScib-2 looks almost ready to go! Modi-1 with doublet Modi-2 Glymabs Avidimab

If you do the maths then iScib-1 in a registration trial, Modi-1 plus doublet with excellent data H1 2025, more Glymab and Avidimab deals. Maybe some people will start thinking a £5 takeover would be a bargain?

The CFO said single digit millions when Genmab go into phase 1 in 2025. So with $6m the up front that likely leaves $6 to $9m on that. Ultimately Redmile decide if a takeover happens, without a thumbs up from them, as they own the magic number on that front of over 25%, 75% of votes special resolution point

CT, Absolutely right. Early deals fund SCIB1 and MODI1, these in turn will fund later products and so on. That's how most businesses grow. A complete takeover may give access to funds earlier but the same principle applies.

MT Hold that thought, not them but matters that would have an equal or greater impact. Many retail just don’t get how the market works. EG I’ll wait for news, what news?, data, takeover, big up front deal, acquisition of a platform etc. Each of those attracts more buying than shares sold (acquisition aside as it’s too late then), and higher prices than sold prices. You have a bunch of existing retail who sold X number millions of shares, with a percentage going into long term hands, meaning they can’t all get them back together and will likely pay higher prices on positive news. That point and in a positive trend, trying to buy against a growing number of investors, good luck there if the market can’t find stock. Scancell was, and is still largely unknown in the retail world, multiples of current active retail could appear overnight as buyers.

Chilltime,I have been paying attention for the past 12 years. I am fully aware of POTENTIAL funding sources. LD has spelled these out - non-dilutive deal, dilutive fund raise or a takeover. The wording of Inans post suggested something was imminent which, unless he has inside information is misleading.

Nothing yet Plasybryn! Good data and interest from big pharma, maybe a takeover should do the job though.

I agree 888. Possibly a complete takeover.

"This approval marks another milestone for Scancell, and the promising efficacy, safety and tolerability study generated from earlier cohorts underscore our belief that our Modi-1 cancer vaccine has the potential to deliver a step change in the treatment of renal and other hard-to-treat cancers." HTTPS://www.proactiveinvestors.co.uk/companies/news/1048645/royal-mail-takeover-still-faces-considerable-political-roadblocks-1048645.html

Ivy has experience of a takeover ... MTFB taken over by Government receivers so i guess i should listen

a non hostile takeover is a BOD approach

Morning Inanaco o makes a very valid point about the pte enticing of a hostile takeover. However he also proves the point that a takeover approach which is acceptable and has the support of RM and Vulpes is a formality as they control the future here. We can disagree over what sum would be enough to illicit RN and Vulpes support but I suspect it would be much less than sone of the more fanciful valuations on here

'market says no' ..............,... Markets don't talk or pass judgements on companies Dominic. They only have 2 metrics (price and time). They move in 'predictable' patterns based on the fear and greed of traders...irrespective of future product potential or external news. Once a stock bottoms and starts to rise, the same 'predictable' patterns take place in the opposite direction. It is therefore impossible to miss the boat on a trading stock. There are ALWAYS opportunities to buy and sell at good times. The only way to miss the boat is on a complete company takeover. That's because the stock is then no longer traded. Buying a stock solely on hope of takeover is rarely a good idea however.